<?xml version="1.0"?>
<PortfolioData PortfolioVersion="Pipeline Snapshot as of January 30, 2024">
<Rows>
<Row Compound_Name="aztreonam-avibactam (PF-06947387)" Business_Segment="Biopharma" Therapeutic_Area="Anti-Infectives" Mechanism_of_Action="Beta lactam/beta lactamase inhibitor" Indication="cIAI, HAP/VAP, cUTI including pyelonephritis and infections due to aerobic gram-negative organisms in adult patients (ACCELERATED ASSESSMENT - E.U.)" Phase_of_Development="Registration" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PAXLOVID" Business_Segment="Biopharma" Therapeutic_Area="Anti-Infectives" Mechanism_of_Action="SARS-CoV-2 3CL protease inhibitor (oral COVID-19 treatment)" Indication="COVID-19 Infection (pediatric)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="sisunatovir (PF-07923568)" Business_Segment="Biopharma" Therapeutic_Area="Anti-Infectives" Mechanism_of_Action="Respiratory syncytial virus fusion inhibitor" Indication="Respiratory Syncytial Virus infection in (Adults) (FAST TRACK - U.S.)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="sisunatovir (PF-07923568)" Business_Segment="WRDM" Therapeutic_Area="Anti-Infectives" Mechanism_of_Action="Respiratory syncytial virus fusion inhibitor" Indication="Respiratory Syncytial Virus infection (Pediatric) (FAST TRACK - U.S.)" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-07817883" Business_Segment="WRDM" Therapeutic_Area="Anti-Infectives" Mechanism_of_Action="SARS-CoV-2 3CL protease inhibitor (oral COVID-19 treatment)" Indication="COVID-19 Infection (FAST TRACK - U.S.)" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="CTB+AVP (PF-07612577)" Business_Segment="WRDM" Therapeutic_Area="Anti-Infectives" Mechanism_of_Action="Beta lactam/Beta lactamase inhibitor" Indication="Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis (FAST TRACK - U.S.)" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="LITFULO (ritlecitinib)" Business_Segment="Biopharma" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="JAK3/TEC inhibitor" Indication="Vitiligo" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="Dazukibart (PF-06823859)" Business_Segment="Biopharma" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="interferon, beta 1, fibroblast (IFNB1) blocker" Indication="Dermatomyositis, Polymyositis  (Biologic) (ORPHAN - U.S., E.U., PRIME - E.U.)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="fordadistrogene movaparvovec (PF-06939926)" Business_Segment="Biopharma" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="Gene therapy, minidystrophin" Indication="Duchenne Muscular Dystrophy Ambulatory (Biologic) (FAST TRACK, RPD - U.S.; ORPHAN - U.S., E.U.)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="fordadistrogene movaparvovec (PF-06939926)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="Gene therapy, minidystrophin" Indication="Duchenne Muscular Dystrophy Ambulatory (Biologic) (2-3 year-old boys)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="LITFULO (ritlecitinib)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="JAK3/TECinhibitor" Indication="Ulcerative Colitis" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="LITFULO (ritlecitinib)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="JAK3/TECinhibitor" Indication="Crohn's Disease" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="Dekavil" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="IL-10" Indication="Rheumatoid Arthritis (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="VELSIPITY (etrasimod)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="S1P inhibitor" Indication="Crohn's disease" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="VELSIPITY (etrasimod)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="S1P inhibitor" Indication="Eosinophilic Esophagitis" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="VELSIPITY (etrasimod)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="S1P inhibitor" Indication="Atopic Dermatitis" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="VELSIPITY (etrasimod)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="S1P inhibitor" Indication="Alopecia Areata" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-06835375" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="anti-CXCR5" Indication="Immune Thrombocytopenic Purpura (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07275315" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="anti-IL-4/ IL-13/ TSLP" Indication="Atopic Dermatitis (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07264660" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="anti-IL-4/ IL-13/ IL-33" Indication="Atopic Dermatitis (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="Dazukibart (PF-06823859)" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="interferon, beta 1, fibroblast (IFNB1) blocker" Indication="Lupus (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-06835375" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="anti-CXCR5" Indication="Lupus (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-07054894" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="CCR6 antagonist" Indication="Inflammatory Bowel Disease" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07261271" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="p40/TL1a bi-specific" Indication="Inflammatory Bowel Disease (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07899895" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="SIK inhibitor" Indication="Ulcerative Colitis" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-07868489" Business_Segment="WRDM" Therapeutic_Area="Inflammation &amp; Immunology" Mechanism_of_Action="anti-BMP9" Indication="Pulmonary Arterial Hypertension (Biologic) (ORPHAN - U.S.)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="fidanacogene elaparvovec (PF-06838435)" Business_Segment="Biopharma" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Gene therapy, coagulation factor IX (F9)" Indication="Hemophilia B (Biologic) (RMAT, BREAKTHROUGH - U.S., ORPHAN - U.S., E.U.)" Phase_of_Development="Registration" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="marstacimab (PF-06741086)" Business_Segment="Biopharma" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Anti-tissue factor pathway inhibitor" Indication="Hemophilia (Biologic) (FAST TRACK - U.S.; ORPHAN - U.S., E.U.)" Phase_of_Development="Registration" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="NGENLA (somatrogon)" Business_Segment="Biopharma" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Human growth hormone agonist" Indication="Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="giroctocogene fitelparvovec (PF-07055480)" Business_Segment="Biopharma" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Gene therapy, coagulation factor VIII (F8)" Indication="Hemophilia A (Biologic) (RMAT, FAST TRACK, ORPHAN - U.S., E.U.)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="Inclacumab (PF-07940370)" Business_Segment="Biopharma" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Anti-P-selectin inhibitor" Indication="Sickle Cell Disease (Biologic) (ORPHAN - U.S., RARE PEDIATRIC DISEASE - U.S.)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="Oxbryta (voxelotor)" Business_Segment="Biopharma" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="HbS polymerization inhibitor" Indication="Sickle Cell Disease - Pediatric" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="ZAVZPRET (zavegepant) (oral)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="calcitonin gene-related peptide (CGRP) receptor antagonist" Indication="Migraine Prevention" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="ervogastat (PF-06865571)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Diacylglycerol O-Acyltransferase 2 (DGAT2) inhibitor" Indication="Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="ervogastat (PF-06865571) + clesacostat (PF-05221304)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Diacylglycerol O-Acyltransferase 2 (DGAT2) inhibitor; Acetyl CoA-Carboxylase (ACC) inhibitor" Indication="Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK - U.S.)" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="danuglipron (PF-06882961)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Glucagon-like peptide 1 receptor (GLP-1R) agonist" Indication="Type 2 Diabetes Mellitus" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="danuglipron (PF-06882961)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Glucagon-like peptide 1 receptor (GLP-1R) agonist" Indication="Obesity" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="ponsegromab (PF-06946860)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Growth Differentiation Factor 15 (GDF15) monoclonal antibody" Indication="Cancer Cachexia (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="ponsegromab (PF-06946860)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Growth Differentiation Factor 15 (GDF15) monoclonal antibody" Indication="Heart Failure (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-07940367 (GBT021601)" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="HbS polymerization inhibitor" Indication="Sickle Cell Disease (ORPHAN - U.S.)" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07258669" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Melanocortin-4 receptor (MC4R) antagonist" Indication="Malnutrition" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07328948" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor" Indication="Heart Failure with Preserved Ejection Fraction" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07853578" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="PNPLA3 modulator" Indication="Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07293893" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="AMPK?3 activator" Indication="Heart Failure" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-06954522" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Glucagon-like peptide 1 receptor (GLP-1R) agonist" Indication="Type 2 Diabetes Mellitus" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07976016" Business_Segment="WRDM" Therapeutic_Area="Internal Medicine" Mechanism_of_Action="Weight loss agent" Indication="Obesity" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TIVDAK (tisotumab vedotin)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="TF-directed antibody-drug conjugate" Indication="Recurrent or Metastatic Cervical Cancer (innovaTV 301) (Biologic) (PRIORITY REVIEW - U.S.)" Phase_of_Development="Registration" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="IBRANCE (palbociclib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK 4,6 kinase inhibitor" Indication="ER+/HER2+ Metastatic Breast Cancer(PATINA)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="Anti-PD-1" Indication="Non-Muscle-Invasive Bladder Cancer (CREST) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="TALZENNA (talazoparib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="PARP inhibitor" Indication="Combo w/ XTANDI (enzalutamide) for DNA Damage Repair (DDR)-Deficient Metastatic Castration Sensitive Prostate Cancer (TALAPRO-3)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="BRAFTOVI (encorafenib) + ERBITUX (cetuximab) + chemotherapy" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="BRAF kinase inhibitor" Indication="1st line BRAF-Mutant Metastatic Colorectal Cancer (BREAKWATER)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="ELREXFIO (elranatamab-bcmm)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="BCMA-CD3 bispecific antibody" Indication="Multiple Myeloma Double-Class Exposed (MM-5) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="ELREXFIO (elranatamab-bcmm)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="BCMA-CD3 bispecific antibody" Indication="Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (MM-7) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="ELREXFIO (elranatamab-bcmm)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="BCMA-CD3 bispecific antibody" Indication="Newly Diagnosed Multiple Myeloma Transplant-Ineligible (MM-6) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="Product Enhancement"/>
<Row Compound_Name="vepdegestrant (ARV-471)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="ER-targeting PROTAC protein degrader" Indication="ER+/HER2- Metastatic Breast Cancer  (VERITAC 2)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="IBRANCE + vepdegestrant (ARV-471)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK 4,6 kinase inhibitor ER-targeting PROTAC protein degrader" Indication="ER+/HER2- Metastatic Breast Cancer (VERITAC 1)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PADCEV (enfortumab vedotin)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="Nectin-4 directed antibody-drug conjugate" Indication="Cisplatin-Ineligible/Decline Muscle-Invasive Bladder Cancer (EV-303) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PADCEV (enfortumab vedotin)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="Nectin-4 directed antibody-drug conjugate" Indication="Cisplatin-Eligible Muscle-Invasive Bladder Cancer (EV-304) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="HER2+ Adjuvant Breast Cancer (CompassHER2 RD)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="2L/3L HER2+ Metastatic Breast Cancer (HER2CLIMB-02)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="1L HER2+ Maintenance Metastatic Breast Cancer (HER2CLIMB-05)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="1L HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03)" Phase_of_Development="Phase 3" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="Disitamab vedotin (DV)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2-directed antibody-drug conjugate" Indication="1L HER2 (=IHC1+) Metastatic Urothelial Cancer (SGNDV-001) (Biologic)" Phase_of_Development="Phase 3" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="vepdegestrant (ARV-471)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="ER-targeting PROTAC protein degrader" Indication="ER+/HER2- Early Breast Cancer" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement"/>
<Row Compound_Name="maplirpacept (TTI-622)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="CD47-SIRPa fusion protein" Indication="Hematological Malignancies (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-06821497 + enzalutamide" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="EZH2 inhibitor" Indication="Prostate Cancer" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07220060" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK4 inhibitor" Indication="Breast Cancer Metastatic" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PADCEV (enfortumab vedotin)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="Nectin-4 directed antibody-drug conjugate" Indication="Locally Advanced or Metastatic Solid Tumors  (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TIVDAK (tisotumab vedotin)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="TF directed antibody-drug conjugate" Indication="Advanced Solid Tumors (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="2L+ Metastatic Urothelial Cancer (HER2 Expression)" Phase_of_Development="Phase 2" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="Locally Advanced or Metastatic Solid Tumors with HER2 Alterations" Phase_of_Development="Phase 2" Compound_Type="Vaccine" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="Disitamab vedotin (DV)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2-directed antibody-drug conjugate" Indication="2L+ Urothelial Cancer with HER2 Expression (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="Disitamab vedotin (DV)" Business_Segment="Biopharma" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2-directed antibody-drug conjugate" Indication="Locally Advanced or Metastatic Solid Tumors with HER2 Expression (Biologic)" Phase_of_Development="Phase 2" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-06940434" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="Integrin alpha-V/beta-8 antagonist" Indication="Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07104091" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK2 inhibitor" Indication="Breast Cancer Metastatic" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07248144" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="KAT6 epigenetic modifier" Indication="Breast Cancer Metastatic" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07284892" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="SHP2 tyrosine phosphatase inhibitor" Indication="Solid Tumors" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07104091 + PF-07220060" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK2 + CDK4 inhibitors" Indication="Breast Cancer Metastatic" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07799933" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="BRAF Class 1 and Class 2 inhibitor" Indication="Solid Tumors" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07104091" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK2 inhibitor" Indication="Ovarian Cancer" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-07220060 + enzalutamide" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CDK4 inhibitor" Indication="Prostate Cancer" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-07799544" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="MEK brain penetrant inhibitor" Indication="Solid Tumors" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07248144 + PF-07220060" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="KAT6 epigenetic modifier + CDK4 inh" Indication="Breast Cancer Metastatic" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PADCEV (enfortumab vedotin)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="Nectin-4 directed antibody-drug conjugate" Indication="Urothelial Cancer (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TUKYSA (tucatinib)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="HER2 tyrosine kinase inhibitor" Indication="HER2+ Gastrointestinal Cancers (SGNTUC-024)" Phase_of_Development="Phase 1" Compound_Type="Small Molecule" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PADCEV (enfortumab vedotin)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="Nectin-4 directed antibody-drug conjugate" Indication="BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="TIVDAK (tisotumab vedotin)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="Tissue Factor-directed antibody-drug conjugate" Indication="Recurrent or Metastatic Cervical Cancer (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-08046049 (SGN-BB228)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CD228-directed antibody-Anticalin bispecific protein3" Indication="Advanced Melanoma and Other Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="SGN-B6A" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="Integrin beta-6-directed antibody-drug conjugate" Indication="Advanced Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="SGN-B7H4V" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="B7H4-directed antibody-drug conjugate" Indication="Advanced Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-08046052 (SGN-EGFRd2)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="EGFR-targeted bispecific gamma delta T-cell engager" Indication="Advanced Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-08046054 (SGN-PDL1V)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="PD-L1-directed antibody-drug conjugate" Indication="Advanced Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-08046040 (SGN-CD70)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="Non-fucosylated CD70-directed antibody" Indication="Myelodysplastic Syndrome and Acute Myeloid Leukemia (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-08046050 (SGN-CEACAM5C)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CEACAM5-directed antibody-drug conjugate" Indication="Advanced Solid Tumors (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-08046045 (SGN-35T)" Business_Segment="WRDM" Therapeutic_Area="Oncology" Mechanism_of_Action="CD-30 directed antibody-tripeptide MMAE conjugate" Indication="Advanced Solid Tumors and Lymphomas (Biologic)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="VTX-801" Business_Segment="WRDM" Therapeutic_Area="Rare Diseases/NMH" Mechanism_of_Action="Recombinant AAV (rAAV) vector-based gene therapy" Indication="Wilson Disease (Biologic) (FAST TRACK - U.S., ORPHAN - U.S.)" Phase_of_Development="Phase 1" Compound_Type="Biologic" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="COVID-19 Vaccine" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="COVID-19 Infection (in collaboration with BioNTech)(U.S. - 5 - 11 years of age)" Phase_of_Development="Registration" Compound_Type="Vaccine" Submission_Type="Product Enhancement"/>
<Row Compound_Name="COVID-19 Vaccine" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="COVID-19 Infection (in collaboration with BioNTech)(U.S. - children 6 months to 4 years of age)" Phase_of_Development="Registration" Compound_Type="Vaccine" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-06425090" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - protein subunit" Indication="Primary Clostridioides difficile Infection (FAST TRACK - U.S.)" Phase_of_Development="Phase 3" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07307405" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - protein subunit" Indication="Lyme Disease (FAST TRACK - U.S.)" Phase_of_Development="Phase 3" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07252220" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="Influenza (adults)" Phase_of_Development="Phase 3" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="COVID-19 Vaccine" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="COVID-19 Infection (in collaboration with BioNTech)(U.S. - 6 months through 11 years of age)" Phase_of_Development="Phase 3" Compound_Type="Vaccine" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-07926307" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="Combination COVID-19 &amp; Influenza (in collaboration with BioNTech) (FAST TRACK - U.S.)" Phase_of_Development="Phase 3" Compound_Type="Vaccine" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="ABRYSVO" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - protein subunit" Indication="Respiratory Syncytial Virus Infection (18-59 years of age)" Phase_of_Development="Phase 3" Compound_Type="Vaccine" Submission_Type="Product Enhancement" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-06760805" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - polysaccharide conjugate" Indication="Invasive Group B Streptococcus Infection (maternal) (BREAKTHROUGH, FAST TRACK - U.S., PRIME - EU)" Phase_of_Development="Phase 2" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07960613" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - protein subunit and mRNA" Indication="Combination Respiratory Syncytial Virus &amp; modRNA COVID-19" Phase_of_Development="Phase 2" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07845104" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - saRNA" Indication="Influenza (adults)" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07941314" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - protein subunit and mRNA" Indication="Combination Respiratory Syncytial Virus &amp; Influenza (adults)" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="PF-07911145" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="Varicella (in collaboration with BioNTech)" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity"/>
<Row Compound_Name="ABRYSVO" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - protein subunit" Indication="Respiratory Syncytial Virus Infection (pediatric)" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="Product Enhancement"/>
<Row Compound_Name="PF-07872412" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - polysaccharide conjugate" Indication="Pneumococcal Infection (FAST TRACK - U.S.)" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>
<Row Compound_Name="PF-07985819" Business_Segment="WRDM" Therapeutic_Area="Vaccines" Mechanism_of_Action="Prophylactic vaccine - mRNA" Indication="Pandemic influenza" Phase_of_Development="Phase 1" Compound_Type="Vaccine" Submission_Type="New Molecular Entity" Project_Advanced_or_is_New="x"/>



</Rows>
</PortfolioData>
